Matthew B. Stern
Stern, Matthew B.
Stern, Matthew B., 19..-....
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
Stern, Matthew B., 1952-....
VIAF ID: 194873829 (Personal)
Permalink: http://viaf.org/viaf/194873829
Preferred Forms
-
100 0 _
‡a
Matthew B. Stern
-
200 _ |
‡a
Stern
‡b
Matthew B.
-
100 1 _ ‡a Stern, Matthew B.
-
100 1 _
‡a
Stern, Matthew B.
-
100 1 _ ‡a Stern, Matthew B.
-
100 1 _
‡a
Stern, Matthew B.
-
100 1 _ ‡a Stern, Matthew B.
-
100 1 0
‡a
Stern, Matthew B.
-
100 1 _
‡a
Stern, Matthew B.,
‡d
19..-....
-
100 1 _
‡a
Stern, Matthew B.,
‡d
1952-....
4xx's: Alternate Name Forms (2)
Works
| Title | Sources |
|---|---|
| [99mTc]TRODAT-1 SPECT imaging correlates with odor identification in early Parkinson disease. |
|
| Beyond the decade of the brain : Emerging therapies in neurologic disease;Parkinson's,Alzheimer's,stroke and epilepsy |
|
| The changing standard of care in Parkinson's disease : current concepts and controversies |
|
| Clinical and therapeutic aspects of parkinsonism : international symposium, Moscou, October 21-23, 1991 |
|
| The Comprehensive management of Parkinson's disease, c1988: |
|
| Deep brain stimulation for Parkinson's disease |
|
| Missing ligand model in autologous stem cell transplantation |
|
| Mitochondrial Polymorphisms Significantly Reduce the Risk of Parkinson Disease |
|
| Montreal cognitive assessment performance in patients with Parkinson's disease with "normal" global cognition according to mini-mental state examination score |
|
| Movement disorder society criteria for clinically established early Parkinson's disease |
|
| Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease. |
|
| Multisite randomized trial of deep brain stimulation |
|
| Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study |
|
| Natural history of multiple system atrophy in the USA: a prospective cohort study |
|
| Odor identification deficits are associated with increased risk of neuropsychiatric complications in patients with Parkinson's disease |
|
| Olfactory testing differentiates between progressive supranuclear palsy and idiopathic Parkinson's disease |
|
| Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease |
|
| Order of application and liver toxicity in patients given BU and CY containing conditioning regimens for allogeneic hematopoietic SCT |
|
| Parkin mutations and susceptibility alleles in late-onset Parkinson's disease |
|
| Parkinsonian syndromes |
|
| Parkinsonism secondary to bilateral striatal fungal abscesses |
|
| Parkinson's Disease Biomarkers: Where Are We and Where Do We Go Next? |
|
| Partial deficit of pantothenate kinase 2 catalytic activity in a case of tremor-predominant neurodegeneration with brain iron accumulation |
|
| Pattern of care of blood donors with early-uncomplicated hereditary haemochromatosis in a Swiss blood donation centre |
|
| The Penn Parkinson's Daily Activities Questionnaire-15: Psychometric properties of a brief assessment of cognitive instrumental activities of daily living in Parkinson's disease |
|
| Phenylthiocarbamide (PTC) perception in Parkinson disease. |
|
| Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease |
|
| Potential outcome measures and trial design issues for multiple system atrophy |
|
| Pre-emptive diagnosis and treatment of fungal infections--evaluation of a single-centre policy. |
|
| Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers. |
|
| Preclinical diagnosis of Parkinson's disease: are we there yet? |
|
| Prognostic impact of iron parameters in patients undergoing allo-SCT |
|
| Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation |
|
| Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms |
|
| Rasagiline improves quality of life in patients with early Parkinson's disease |
|
| Regional cerebral glucose metabolism in aphemia: a case report |
|
| Respiratory failure following stereotactic neurosurgery in a 53-year-old woman |
|
| The scientific and clinical basis for the treatment of Parkinson disease (2009). |
|
| Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis |
|
| Sicca symptoms and their impact on quality of life among very long-term survivors after hematopoietic SCT. |
|
| Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease. |
|
| Subthalamic nucleus deep brain stimulation for severe idiopathic dystonia: impact on severity, neuropsychological status, and quality of life |
|
| Suicide ideation and behaviours after STN and GPi DBS surgery for Parkinson's disease: results from a randomised, controlled trial |
|
| Supranuclear vertical gaze abnormalities in sporadic Creutzfeldt-Jakob disease |
|
| Surgical management of movement disorders |
|
| Targeting for thalamic deep brain stimulator implantation without computer guidance: assessment of targeting accuracy |
|
| Test characteristics of the 15-item geriatric depression scale and Hamilton depression rating scale in Parkinson disease |
|
| Therapy guided by symptoms for Parkinson's disease. |
|
| Toward a redefinition of Parkinson's disease |
|
| Treatment of levodopa-induced dyskinesias with donepezil |
|
| Tumor incidence in related hematopoietic stem cell donors |
|
| Undulating Lingual Dyskinesia With Symptomatic Palatal Tremor and Inferior Olivary Hypertrophy Following Cerebellar Hemisphere Hematoma |
|
| Unresolved issues in Parkinson's disease |
|
| Use of latent variable modeling to delineate psychiatric and cognitive profiles in Parkinson disease |
|
| Use of natural killer cells in hematopoetic stem cell transplantation |
|
| Validation of an instrument to measure older adults' expectations regarding movement (ERM). |
|
| Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease |
|
| Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies |
|
| The α-synuclein gene is not a major risk factor in familial Parkinson disease |
|
